Mallmin H, Ljunghall S, Larsson K, Lindh E
Department of Orthopaedics, University Hospital, Uppsala, Sweden.
Ups J Med Sci. 1991;96(3):205-12. doi: 10.3109/03009739109179272.
The bisphosphonates are potent inhibitors of osteoclastic bone resorption that mainly have been used for treatment of hypercalcaemia secondary to malignancy. We have performed a controlled dose-finding study of oral pamidronate that was given to 60 patients with a history of fracture of the distal forearm, an enhanced bone turnover and a lowered bone mineral density. Different doses of pamidronate, 75 mg and 150 mg daily, or placebo were given to parallel groups. Fasting specimens of blood and urine were collected before the treatment period and at regular intervals. Oral pamidronate caused a dose-related reduction on the biochemical markers of bone resorption, i.e. fasting urinary calcium, hydroxyproline, pyridinoline and deoxypyridinoline that was seen already after the first week. The inhibition was evident during the treatment period and 4 weeks thereafter but not 12 weeks after cessation of therapy. Also the levels of serum osteocalcin, a marker of bone formation, were lowered during treatment with the higher dose.
双膦酸盐是破骨细胞性骨吸收的强效抑制剂，主要用于治疗继发于恶性肿瘤的高钙血症。我们对60例有远端前臂骨折史、骨转换增强和骨矿物质密度降低的患者进行了口服帕米膦酸的对照剂量探索研究。将不同剂量的帕米膦酸（每日75毫克和150毫克）或安慰剂给予平行组。在治疗期之前及定期采集空腹血样和尿样。口服帕米膦酸使骨吸收的生化标志物即空腹尿钙、羟脯氨酸、吡啶啉和脱氧吡啶啉出现剂量相关的降低，这在第一周后就已可见。这种抑制在治疗期及之后4周明显，但在治疗停止12周后则不明显。高剂量治疗期间，作为骨形成标志物的血清骨钙素水平也降低。
